Country: UNITED KINGDOM | Region: EUROPE | Type: Pricing & Reimbursement | Keywords: #emtricitabine/tenofovirdisoproxil #gilead #hiv #impacttrial #mylan #nhsengland #prep
PRICENTRIC BRIEF:
- From April, pre-exposure prophylaxis (PrEP) will be available on NHS England for patients at a greater risk of catching HIV, announced Health Secretary Matt Hancock
- NHS England will cover the costs of the drug—according to the Department of Health, local authorities will receive GBP 16 million in 2020 and 2021 to deliver PrEP, in addition to the local authority public health grant
- PrEP, specifically Mylan’s generic version of Gilead’s Truvada (emtricitabine/tenofovir disoproxil), has already been made available in England since 2017 through the three-year IMPACT trial in over 20,000 participants who are at high risk of HIV, which is due to conclude in October of this year
THE DETAILS
LONDON, United Kingdom – From April, pre-exposure prophylaxis (PrEP) will be available on NHS England for patients at a greater risk of catching HIV, announced Health Secretary Matt Hancock.
Hancock commented, “While it is encouraging to see HIV transmissions continue to fall across the UK, I am determined to do more, and end HIV transmission. So, we are rolling out PrEP and making it available across the country—with evidence showing it almost completely eradicates the chance of getting HIV. This will benefit tens of thousands of people’s lives and drive us towards our ambition of zero HIV transmissions in this decade.”
It is estimated that there are 103,800 people currently living with HIV in the UK, of whom 7,500 are thought to be unaware of their status.
NHS England will cover the costs of the drug. According to the Department of Health, local authorities will receive GBP 16 million in 2020 and 2021 to deliver PrEP, in addition to the local authority public health grant.
PrEP, specifically Mylan’s generic version of Gilead’s Truvada (emtricitabine/tenofovir disoproxil), has already been made available in England since 2017 through the three-year IMPACT trial in over 20,000 participants who are at high risk of HIV, which is due to conclude in October of this year.
Both Wales and Scotland already cover PrE
Learn more about Pricentric One and our Global Pricing Solutions!
Contact us with your questions and global pricing needs, and an expert will follow up shortly.